Shanghai Shyndec subsidiary expands Vitamin B6 offerings, elects new leadership

Shanghai Shyndec Pharmaceutical's wholly-owned subsidiary, Sinopharm Group RongSheng Pharmaceutical Co., Ltd., announced the approval of a supplementary application for its Vitamin B6 injection (1ml:0.1g). This approval expands the product's specifications and signifies its passage of generic drug quality and efficacy consistency evaluation. Cumulative R&D investment for this project by Guoyao Rongsheng totals RMB 408.85萬元.

This development is expected to bolster the product's market expansion and sales, although it is not anticipated to significantly impact current operating performance. Domestic sales of Vitamin B6 injections reached approximately RMB 3.04亿元 in 2024.

Concurrently, the company's eighth board of directors convened, approving the election of Cai Maisong as vice chairman, whose term will run until the current board's expiration. Cai, born in 1970 with a background in pharmaceutical sciences and business administration, also joins the board's strategy and investment committee. The board also approved the 2025 internal control system construction and supervision evaluation plan.